Table 3.

Willingness to utilize the off-label drug as molecular-based recommended therapy identified by comprehensive genomic profiling

	Total		Cancer patients		Medical professionals		Non-cancer volunteers
	N	%	N	%	N	%	N	%
Number of people	1261	100	419	100	430	100	412	100
No cost burden
Very positive	157	13	52	12	65	15	40	10
Positive	530	42	163	39	202	47	165	40
Fair	473	38	169	40	136	32	168	41
Negative	85	7	34	8	22	5	29	7
Not at all	16	1	1	0	5	1	10	2
Cost ¥200,000 per month (approximately $US1,300/month)
Very positive	40	3	11	3	20	5	9	2
Positive	218	17	51	12	114	27	53	13
Fair	566	45	198	47	179	42	189	46
Negative	341	27	131	31	94	22	116	28
Not at all	96	8	28	7	23	5	45	11
Cost ¥1,000,000 per month (approximately $US6,700/month)
Very positive	19	2	6	1	10	2	3	1
Positive	93	7	19	5	59	14	15	4
Fair	460	37	137	33	161	37	162	39
Negative	422	34	166	40	123	29	133	32
Not at all	267	21	91	22	77	18	99	24